114 related articles for article (PubMed ID: 8529742)
21. Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma.
Akpolat I; Bariş YS; Yilmaz AF; Bakirtaş M; Saylik A; Karagöz F; Kandemir B
Neoplasma; 1998; 45(6):365-8. PubMed ID: 10210109
[TBL] [Abstract][Full Text] [Related]
22. Flow cytometric DNA ploidy analysis in canine transitional cell carcinoma of urinary bladders.
Clemo FA; DeNicola DB; Carlton WW; Morrison WB; Walker E
Vet Pathol; 1994 Mar; 31(2):207-15. PubMed ID: 8203084
[TBL] [Abstract][Full Text] [Related]
23. Ki-67 scores and AgNor counts in transitional cell carcinoma of the bladder: apparent lack of prognostic value.
Zambelli S; Zanin A; Gaglio A; Zai G; Bosco E; Andrion A; Magnani C
Arch Ital Urol Androl; 1993 Dec; 65(6):665-70. PubMed ID: 8312949
[TBL] [Abstract][Full Text] [Related]
24. DNA-Flow cytometric analysis of bladder TCC using paraffin-embedded tissues.
Wu L; Lochhead A; Yang J; Ow KT; Russell PJ
Urol Int; 1998 Aug; 60(4):208-15. PubMed ID: 9701732
[TBL] [Abstract][Full Text] [Related]
25. Gallbladder cancer. A comparative study among clinicopathologic features, AgNORs, and DNA content analysis.
Nishizawa-Takano JE; Ayabe H; Hatano K; Yamaguchi H; Tagawa Y
Dig Dis Sci; 1996 May; 41(5):840-7. PubMed ID: 8625752
[TBL] [Abstract][Full Text] [Related]
26. DNA ploidy pattern and cell cycle stage of tumor cells in soft-tissue sarcomas: clinical implications.
Kuratsu S; Tomita Y; Myoui A; Uchida A; Ono K; Aozasa K
Oncology; 1995; 52(5):363-70. PubMed ID: 7637952
[TBL] [Abstract][Full Text] [Related]
27. Interphase nucleolar organizer regions in the evaluation of serosal cavity effusions.
Carrillo R; Sneige N; el-Naggar AK
Acta Cytol; 1994; 38(3):367-72. PubMed ID: 8191825
[TBL] [Abstract][Full Text] [Related]
28. Nucleolar and argyrophilic nucleolar organizer region counts in urothelial carcinomas with special emphasis on grade II tumors.
Helpap B; Loesevitz L; Bulatko A
Virchows Arch; 1994; 425(3):265-9. PubMed ID: 7812512
[TBL] [Abstract][Full Text] [Related]
29. Deoxyribonucleic acid content and survival rates of patients with transitional cell carcinoma of the bladder.
al-Abadi H; Nagel R
J Urol; 1994 Jan; 151(1):37-42. PubMed ID: 8254829
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.
Shariat SF; Weizer AZ; Green A; Laucirica R; Frolov A; Wheeler TM; Lerner SP
Urology; 2000 Nov; 56(5):735-40. PubMed ID: 11068290
[TBL] [Abstract][Full Text] [Related]
31. AgNOR counts and their combination with flow cytometric analyses and clinical parameters as a prognostic indicator in breast carcinoma.
Rzymowska J
Tumori; 1997; 83(6):938-42. PubMed ID: 9526588
[TBL] [Abstract][Full Text] [Related]
32. [Image cytometric DNA analysis in bladder tumors].
Yamamoto S; Akiyama A; Ito T; Miki M; Furusato M; Aizawa S
Nihon Hinyokika Gakkai Zasshi; 1996 Aug; 87(8):1026-31. PubMed ID: 8831209
[TBL] [Abstract][Full Text] [Related]
33. DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder.
Deliveliotis C; Georgoulakis J; Skolarikos A; Trakas N; Varkarakis J; Albanis S; Protogerou B; Bamias A
Urol Res; 2005 Feb; 33(1):39-43. PubMed ID: 15258707
[TBL] [Abstract][Full Text] [Related]
34. Cytomorphometric and flow cytometric analysis of bladder transitional cell carcinoma using acridine orange fluorochrome: correlation with histopathology and clinical behavior.
Yu DS; Hsu CM; Chang SY; Ma CP
J Formos Med Assoc; 1992 Feb; 91(2):152-8. PubMed ID: 1364210
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in urachal adenocarcinoma. A study in 41 specimens of DNA status, proliferating cell-nuclear antigen immunostaining, and argyrophilic nucleolar-organizer region counts.
Nakanishi K; Kawai T; Suzuki M; Torikata C
Hum Pathol; 1996 Mar; 27(3):240-7. PubMed ID: 8600037
[TBL] [Abstract][Full Text] [Related]
36. Two-dimensional agnor evaluation as a prognostic variable in urinary bladder carcinoma: a different approach via total agnor area/nucleus area per cell.
Cucer N; Imamoglu N; Tozak H; Demirtas H; Sarac F; Tatlisen A; Oztürk F
Micron; 2007; 38(6):674-9. PubMed ID: 17011198
[TBL] [Abstract][Full Text] [Related]
37. AgNORs in benign, borderline and transitional cell neoplasms of the urinary bladder.
Misra V; Mukherjee J; Gupta SC; Tandon S; Gupta AK
APMIS; 1998 Oct; 106(10):987-92. PubMed ID: 9833702
[TBL] [Abstract][Full Text] [Related]
38. Flow cytometric analysis of deparaffinized nuclei in urinary bladder carcinoma. Comparison with cytogenetic analysis.
Coon JS; Schwartz D; Summers JL; Miller AW; Weinstein RS
Cancer; 1986 Apr; 57(8):1594-601. PubMed ID: 3948130
[TBL] [Abstract][Full Text] [Related]
39. [DNA profile, recurrence rate and progression of superficial G2 cancer of the urinary bladder].
Maier G; Heissler HE; Blech M; Schröter W
Urologe A; 1988 May; 27(3):173-6. PubMed ID: 3407050
[TBL] [Abstract][Full Text] [Related]
40. Argyrophilic nucleolar organizer regions in breast carcinoma. Correlation with DNA flow cytometry, histopathology, and lymph node status.
Mourad WA; Erkman-Balis B; Livingston S; Shoukri M; Cox CE; Nicosia SV; Rowlands DT
Cancer; 1992 Apr; 69(7):1739-44. PubMed ID: 1312892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
